Cox Enterprises invested in digital media company Axios at a $430m valuation while Bristol Myers Squibb helped enzyme drug developer Nitrase Therapeutics boost its series A round to $45m.

Gilead and BeiGene participated in a round for the immuno-oncology therapeutics developer in a round that came seven months after it raised $43m.

Bayer’s Marianne De Backer spoke with GCV’s James Mawson on the latest in the biotech scene.

Corporate-backed financial remittance network operator Lightnet netted over $48m while Callaway Golf Company invested $30m in indoor golfing chain Five Iron Golf.

Norgine, Axa and Debiopharm are in line for exits as the breast cancer diagnostics test provider is aiming to go public to boost research and development and commercial activities.

SoftBank’s Vision Fund 2 led a $59.7m round which will support Aculys in bringing a sleep disorder medication it has licensed to Japan.

Cell therapy developer Hopstem completed a $40m Eli Lilly-backed series B round while cybersecurity technology developer SlashNext secured $26m from investors including Telia and Ayala Group.

The Merck & Co and Roche-backed Duchenne muscular dystrophy drug developer has gone public in an upsized IPO sized at approximately $182m.

Henry Crown and Company achieved an exit as the root canal technology developer listed on the New York Stock Exchange below its IPO range.

Chiesi, Lundbeck and Li-Cor Biosciences scored exits as the oncology therapy developer floated in an upsized $75.6m initial public offering.